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ABSTRACT
Nutrient deprivation strategies have been proposed as an adjuvant therapy for 
cancer cells due to their increased metabolic demand. We examined the specific 
inhibitory effects of amino acid deprivation on the metastatic phenotypes of the 
human triple-negative breast cancer (TNBC) cell lines MDA-MB-231 and Hs 578T, as 
well as the orthotopic 4T1 mouse TNBC tumor model. Among the 10 essential amino 
acids tested, methionine deprivation elicited the strongest inhibitory effects on the 
migration and invasion of these cancer cells. Methionine deprivation reduced the 
phosphorylation of focal adhesion kinase, as well as the activity and mRNA expression 
of matrix metalloproteinases MMP-2 and MMP-9, two major markers of metastasis, 
while increasing the mRNA expression of tissue inhibitor of metalloproteinase 
1 in MDA-MB-231 cells. Furthermore, methionine restriction downregulated the 
metastasis-related factor urokinase plasminogen activatior and upregulated 
plasminogen activator inhibitor 1 mRNA expression. Animals on the methionine-
deprived diet showed lower lung metastasis rates compared to mice on the control 
diet. Taken together, these results suggest that methionine restriction could provide 
a potential nutritional strategy for more effective cancer therapy.
INTRODUCTION
Breast cancer is the second most common form of 
cancer arising in women in worldwide [1]. Recently, the 
mortality rate of breast cancer patients has been declining 
due to early detection methods and improvements in surgery, 
radiation therapy, chemotherapy, and hormone therapies 
[2]. However, some patients show resistance of these 
therapies. Triple-negative breast cancers (TNBC) account 
for 15-20% of all breast cancers. TNBC refers to an absence 
of the expression of three major hormone receptors; the 
estrogen receptor (ER), progesterone receptor (PR), and 
hormone epidermal growth factor receptor 2 (HER-2). A 
number of potent receptor-targeting drugs such as tamoxifen 
and trastuzumab target these receptors, and are therefore 
ineffective for TNBC patients [3]. TNBC is generally more 
aggressive, with higher rates of relapse and lower rate of 
survival in metastatic status [4]. Consequently, patients with 
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TNBC have lower survival rates and a greater risk of the 
disease relapsing within 5 years of diagnosis. Metastasizing 
advanced stage of breast cancer remains very difficult to treat, 
and the ultimate cause of death in many patients is metastasis 
to a distant site, rather than due to the primary tumor [5, 
6]. Therefore, the control of metastasis is a key therapeutic 
approach for extending overall survival. TNBC patients also 
have a higher rate of metastatic recurrence (33.9%) compared 
to other breast cancer patients (20.4%) [7]. Therefore, 
preventing metastasis of TNBC is an excellent strategy for 
curing TNBC patient. Adjuvant therapy to prevent metastasis 
is typically required for the treatment of TNBC.
Cancer cells require larger quantities of nutrient 
resources such as glucose and amino acids than non-
malignant cells, due to their rapid growth and aggressive 
characteristics. The increased rate of glycolysis exhibited 
by many tumors cells is referred to as the Warburg effect 
[8]. Due to the fact that glucose restriction in clinical 
settings can result in systemic toxicity, dietary amino 
acid restriction has emerged as a more viable nutritional 
therapeutic strategy [9]. Limited success has been reported 
with nutrient deprivation strategies against various cancer 
cells that are amino acid-dependent. For example, L-
asparaginase is a chemotherapeutic drug that has been 
used for the treatment of lymphoblastic leukemia [10, 
11]. Methionine is another important amino acid for 
cancer cell. It is the first amino acid of protein and it is 
required for protein synthesis, methylation of DNA and 
polyamine synthesis [12]. Serine starvation also reduces 
cancer cell survival due to oxidative stress, particularly in 
cells lacking p53 [13], while tyrosine and phenylalanine 
restriction have been observed to inhibit B16-BL6 tumor 
growth and metastasis [14, 15]. Taken together, these 
results demonstrate proof-of-concept for amino acid 
restriction as a viable adjuvant therapeutic strategy.
In the present study, we evaluated the effects of amino 
acid deprivation on the migration and invasion of TNBC 
cell lines. Among the 10 essential amino acids tested, 
methionine deprivation caused the strongest inhibitory 
effect on migration and invasion in these cells. Conditions 
of methionine deprivation suppressed metastasis-related 
biomarkers and increased levels of their inhibitors. We 
also analyzed the effects of methionine restriction on lung 
metastasis in an orthotopic mouse metastasis model.
RESULTS
Methionine deprivation inhibits cell migration 
and invasion of MDA-MB-231 and Hs 578T cells
To investigate the effect of deprivation of each 
amino acid in regards to triple negative breast cancer 
(TNBC) cell migration, MDA-MB-231 and Hs 578T cells 
were incubated with each amino acid-deprived media 
formulation for 24 hours. Wound widths at each time point 
were expressed as the percentage relative to the wound 
width at 0 hours in each well (Figure 1A(a) and 1B(a)). 
The relative wound widths of the methionine-deprived 
group were 174% for MDA-MB-231 (Figure 1A(b) and 
131.1% for Hs 578T cells (Figure 1B(b)). The cells of the 
control group migrated to a greater extent than the cells of 
the methionine-deprived group (Figure 1A(c) and 1B(c)).
To examine the effect of deprivation of each amino 
acid on TNBC cell invasiveness, MDA-MB-231 and Hs 
578T cells were incubated with each amino acid-deprived 
media formulation containing BD Matrigel (500 μg/ml) for 
24 hours. The relative wound density (RWD) at each time 
point was expressed as the percentage relative to the wound 
density at 0 hours in each well (Figure 1C(a) and 1D(a)). 
The RWD of the methionine-deprived group was 73.5% for 
MDA-MB-231 (Figure 1C(b)) and 70.2% for Hs 578T cells 
(Figure 3D(b)). The cells of the control group were more 
invasive than the cells of the methionine-deprived group 
(Figure 1C(c) and 1D(c)). Overall, these results indicate that 
methionine deprivation elicits the strongest inhibitory effect 
on cell migration and invasion in these cell lines.
Methionine deprivation has no significant effect 
on cell viability of MDA-MB-231, Hs 578T, or 
MCF 10A cells
Methionine deprivation had no significant effect on 
cell viability for 24 hours in MDA-MB-231 (Figure 2A) 
and Hs 578T cells (Figure 2B) when assessed using MTT 
assay. This suggests that the migration and invasion results 
previously obtained (Figure 1) were a direct result of the 
inhibition of migration and invasion factors, rather than an 
indirect effect of proliferative inhibition. In addition, there 
was no significant difference on cell viability between the 
methionine-deprived group and the control group for 24 
hours when assessed using the normal breast cell line 
MCF 10A (Figure 2C).
Methionine deprivation suppresses FAK 
phosphorylation and activity, in addition to 
mRNA expression of MMP-2 and MMP-9 in 
MDA-MB-231 cells
We subsequently investigated how methionine 
deprivation suppresses cell migration and invasion. We first 
analyzed levels of focal adhesion kinase (FAK), an important 
protein in cell adhesion, motility and metastasis [16]. 
Methionine deprivation effectively inhibited phosphorylation 
of focal adhesion kinase (FAK) after 8 hours (Figure 3A), 
while also causing a reduction of activity and mRNA 
expression of MMP-2 and MMP-9, two extracellular matrix-
degrading enzymes (Figure 3B and 3C). Tissue inhibitor of 
metalloproteinase-1 (TIMP-1) mRNA levels were observed 
to increase in conditions of methionine deprivation (Figure 
3D). Furthermore, mRNA levels of urokinase plasminogen 
activator (uPA) decreased (Figure 3E), while plasminogen 
activator inhibitor-1 (PAI-1) increased (Figure 3F).
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Figure 1: Effect of methionine deprivation on cell migration in MDA-MB-231 and Hs 578T cells. A. Migration assay 
results using MDA-MB-231 cells. The relative wound widths of each amino acid-deprived group were compared with the control group 
over time (a). Comparison of relative wound widths between treatment groups after 24 hours (b). Representative image of a scratch wound 
mask after 24 hours (c). B. Migration assays using Hs578T cells. The relative wound widths of each amino acid-deprived group were 
compared with the control group over time (a). Comparison of the relative wound widths of each amino acid-deprived and control group 
after 24 hours (b). Representative image of a scratch wound mask after 24 hours (c). The wound widths were automatically measured using 
IncuCyte™ software, with the following equation: Wound width (μm) = (N: vertical line of the scratch wound image, w: distance 
between the edges of the scratch wound mask, i: number of 924 horizontal lines of resolution in a scratch wound image). C. Invasion 
assay using MDA-MB-231 cells. The relative wound density of each amino acid-deprived group was compared with the control group over 
time (a). Relative wound densities for each amino acid-deprived group compared with the control group after 24 hours (b). Representative 
image of a scratch wound mask after 24 hours (c). D. Invasion assay using Hs578T cells. The relative wound density of each amino acid-
deprived group was compared with the control group over time (a). Comparison of relative wound densities between treatment groups after 
24 hours (b). Representative image of a scratch wound mask after 24 hours (c). The relative wound density (RWD) is a measure of (%) 
density of the wound region relative to the density of the cell region, which was automatically measured using IncuCyte™ software, with 
the equation as follows: (w(t) = Density of wound region at time, t. c(t) = Density of cell region at time, t). Data represent 
the mean values ± S.D. Mean values with letters (a-e) within a graph are significantly different from each other at p < 0.05.
wiN
1
∑
= ×
−
−
RWD t w t w
c t w
% ( ) 100 { ( ) (0)}
{ ( ) (0)}
Oncotarget67226www.impactjournals.com/oncotarget
Figure 2: Effect of methionine deprivation on cell viability of MDA-MB-231, Hs 578T cells and the non-invasive breast 
cell line MCF 10A. A. Relative cell viability of MDA-MB-231. B. Relative cell viability of Hs 578T. C. Relative cell viability of MCF 
10A. Viability was measured using MTT assay. Data (n = 3) represent the mean values ± S.D. Mean values with letters (a-f) within a graph 
are significantly different from each other at p < 0.05.
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Figure 3: Effect of methionine deprivation on FAK, MMP-2, MMP-9, TIMP-1, uPA, and PAI-1 expression in 
MDA-MB-231 cells. A. Methionine deprivation inhibits phosphorylation of FAK at Tyr 397, a major autophosphorylation site, as 
determined by Western blot. Total FAK was used as a loading control. Cells were incubated in control and methionine-deprived media 
for the indicated durations and harvested simultaneously. The numbers represent ratio between normal and methionine deprivation 
media in each time point. Phosphorylation bands are normalized by total band. Band density was measured by the Image J. B. MMP-
2 and MMP-9 activity was determined by gelatin zymography as described in the Materials and Methods. The numbers represent 
ratio between normal and methionine deprivation media. The bands are quantified by Image J software. C. mRNA levels of MMP-2 
and MMP-9 were analyzed by real-time quantitative PCR. Cells were incubated with control and methionine-deprived media for 
24 hours and RNA was harvested. D. mRNA expression of TIMP-1. E. mRNA expression of uPA. F. mRNA expression of PAI-1. 
Data represent the mean values ± S.D. The asterisks (* or **) indicate a significant difference (p < 0.05 or p< 0.01) between the 
control group and methionine deprivation group.
Oncotarget67228www.impactjournals.com/oncotarget
Methionine deprivation inhibits cell migration 
and invasion in 4T1 cells
We next examined the inhibitory effect of 
methionine deprivation on the migration and invasion of 
4T1 mouse triple negative breast cancer cells. The wound 
width at each time point was expressed as the percentage 
relative to the wound width at 0 hours in each well 
(Figure 4A). The relative wound width of the methionine-
deprived group at 12 hours was 100.9% compared to a 
60% relative wound width for the control group (Figure 
4B). The RWD at each time point was expressed as the 
percentage relative to the wound density of 0 hours in 
each well (Figure 4C), and the RWD of the methionine-
deprived group was 16.4% compared to a 49.1% RWD for 
the control group (Figure 4D). These inhibitory effects of 
methionine deprivation were evident within the same time 
duration that cytotoxicity was absent (Figure 4E).
Methionine deprivation reduces lung metastasis 
of 4T1 cells in BALB/c mice
Tail vein injections of 4T1 cells (2 X 105 cells/
mouse) to the BALB/c mice caused a development of 
tumor nodules in the lungs of the mice. An intake of 0.1% 
methionine in the diet was observed to have no effect, but 
the intake of a methionine-deprivation diet for 10 days 
significantly reduced the number of tumor nodules in 
the lungs (Figure 5A and 5B). The diets were provided 
ad libitum, and the intake of the methionine deprived-diet 
(1.69 g/day/mouse) was found to be lower than that of 
the control diet (2.27 g/day/mouse) (Figure 5C). The body 
weights of the mice between the control and methionine-
deprived group were significantly different after 6 days of 
injection (Figure 5D).
DISCUSSION
Breast cancer has the highest incidence among 
female cancers. Hormonal effects play a pivotal role in 
breast cancer growth. Endocrine therapy utilizing hormone 
receptor inhibitor such as tamoxifen is effective in treating 
breast cancer [17]. However, some types of breast cancer 
are not responsive to tamoxifen. In tamoxifen-resistant 
breast cancer, HER-2-targeted therapy is developed for 
alternative therapy such as trastuzumab [18]. Yet, these 
therapies do not work in 15~20% of breast cancer patients 
[17]. Resistance to drug also develops very easily. The 
breast cancer which does not respond to endocrine and 
HER-2-targeted therapy is called as TNBC [4]. TNBC 
has highly metastatic and aggressive features and there 
is no effective therapy which results in high mortality. 
Therefore, new therapeutic strategies are urgently needed 
for TNBC. In this study, we found methionine restriction 
inhibits metastasis of TBNC, and it may be a good strategy 
to prolong lifespan of TNBC patients.
In this study, we employed two human TNBC cell 
lines, MDA-MB-231 and Hs578T, which are commonly 
studied human cell lines for treatment of triple negative 
breast cancer [19]. We also used the 4T1 orthotopic 
model of TNBC with female BALB/c mice. The tail vein 
metastasis model with 4T1 cells has established itself as a 
relevant model for lung metastasis in breast cancer [20]. 
We screened 10 essential amino acids and observed that 
methionine restriction conferred the highest inhibitory effect 
on migration and invasion of human TNBC cells. These 
inhibitory effects occurred within a short duration after 
treatment initiated, during which the effect of deprivation 
was not observed to be cytotoxic, as evidenced by MTT 
assay for the human TNBC cells and MCF 10A normal 
breast epithelial cells. Furthermore, the effects of methionine 
deprivation on migration, invasion and cell viability were 
confirmed in our 4T1 mouse breast cancer model, and a 
methionine-deprived diet suppressed metastasis to the lungs 
of 4T1 cells in BALB/c mice. Although the body weights 
of methionine-restricted mice were slightly decreased, this 
is unlikely to be the sole factor responsible for the decrease 
in metastasis observed. A previous study reported that a 
methionine-restricted diet negatively impacts the growth 
of animals, but extends the life span of various rat strains. 
The study showed that the life span extension effects of low 
methionine was not due to reduced energy intake, which 
was also observed to a slight degree [21]. Therefore, the 
slight weight loss we observed may be a reasonable side 
effect of a methionine restricted diet.
The Warburg effect refers to the significantly 
increased need for nutrients and stronger metabolic 
processes exhibited by cancer cells [8]. In addition to 
calorie restriction, specific amino acid restriction has been 
used in the past to treat cancer. Methionine-dependency 
of malignant cells were first observed in Walker-256 
carcinosarcoma-transplanted rodents in 1959 [22]. An 
absolute methionine-dependency of human, mouse, 
and rat malignant cells was identified by growth of the 
cells in methionine-depleted and in homocysteine (the 
immediate precursor of methionine)-supplemented media 
(Met- Hcy+). In contrast, normal cells were not affected by 
the Met- Hcy+ media [23]. Other studies have suggested 
that various cancer cells are methionine-dependent, and 
simple dietary depletion of methionine has been shown 
to reduce the proliferation of numerous cancer cell lines 
[9]. For example, methionine starvation has been observed 
to inhibit tumor growth of PC-3 cells, and a methionine 
analogue was shown to potentiate these effects [24]. A 
methionine-restricted diet also suppressed colon cancer 
development in F344 rats [25]. In addition to the growth 
inhibitory effects of methionine depletion, it has also been 
shown to enhance the efficacy of chemotherapeutic agents 
in refractory cancers and TNBC [26, 27]. Furthermore, 
methionine restriction is known to extend the life-span 
of various rat strains, indicating that basic health is not 
threatened by methionine restriction [21, 28].
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Methionine is an essential amino acid necessary 
for mammal development [9]. Normal cells can convert 
homocysteine to methionine. However, cancer cells need 
much more methionine than normal cells do and cannot 
convert enough methionine they need [29]. Another reason 
of cancer cells depend on methionine is that methionine 
is required in polyamine synthesis. Polyamine plays 
an important roles in cell growth and its level has been 
Figure 4: The inhibitory effect of methionine deprivation on migration and invasion of 4T1 cells. A and B. Relative wound 
widths of 4T1 cells were evaluated by migration assay. C and D. The relative wound density in 4T1 cells was determined by invasion assay. 
E. Relative cell viability of 4T1 cells. Data represent the mean values ± S.D. Mean values with letters (a-c) within a graph are significantly 
different from each other at p < 0.05.
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associated with colon, lung, prostate skin and breast cancers. 
Cancer cells cannot produce enough polyamine in methionine 
deprivation. Especially, methylthioadenosine phosphorylase 
(MTAP) is involved polyamine synthesis from methionine 
[12]. Loss of MTAP expression has been observed in many 
cancer cell lines including TNBC [30]. The cancers which 
lose MTAP expression required methionine and cannot grow 
in methionine deprivation [30–32].
Many studies have showed inhibition of growth 
of cancer cell by methionine deprivation [9]. In our 
knowledge, we showed for the first time methionine-
deprivation reduced TNBC migration in vitro and in vivo 
in this study. FAK is required for the signaling pathway 
initiated by the interaction between ECM proteins 
and integrins which induce cell migration [33]. We 
changed normal and methionine free medium. In normal 
medium, the highest phosphorylation of FAK was shown 
and the phosphorylation of FAK decreased in a time-
dependent manner. In the methionine free medium, the 
phosphorylation of FAK also decreased in a time-dependent 
manner but much more than that of normal medium. In the 
same time points, phosphorylation of FAK was decreased 
by methionine deprivation. FAK regulates migration 
related proteins such as MMP-2, MMP-9, TIMP-1, uPA, 
and PAI-1 [34]. MMP-2 and MMP-9 are gelatinase which 
degrade ECM and make cell free to move [35]. TIMP-1 
inhibits MMPs activity [36]. uPA is a serine protease that 
can initiate proteolytic cascades, which result in remodeling 
of basement membrane and ECM allowing cells to move 
[37]. PAI-1 inhibits uPA [38]. Methionine deprivation 
inhibited MMP-2, MMP-9 and uPA, and increased TIMP-1 
and PAI-1. Therefore, methionine is required for TNBC 
migration by regulating FAK.
Taken together, these observations suggest that 
methionine restriction should be regarded as a possible 
adjuvant therapeutic strategy for TNBC treatment. 
Underlying mechanism how methionine deprivation 
inhibits phosphorylation FAK remains to be elucidated. 
Clinical trial is also needed to validate methionine 
deprivation is an effective strategy for TNBC treatment.
Figure 5: Inhibitory effect of a methionine deprived-diet on lung metastasis in BALB/c mice. A and B. Numbers of tumor 
nodules detected. C. Food intake details for each group. D. Mouse body weights. Data (n = 4-5) represent the mean values ± SEM. Mean 
values with letters (a-c) within a graph are significantly different from each other at p < 0.05.
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MATERIALS AND METHODS
Reagents
Dulbecco’s modified eagle medium (DMEM) 
and the amino acid-deprived DMEM formulations 
were purchased from Welgene (Daegu, Korea). Fetal 
bovine serum (FBS), mitomycin C, recombinant human 
epithelial growth factor and insulin solution were 
obtained from Sigma-Aldrich (St.Louis, MO). Dialyzed 
FBS (dFBS), HEPES, and anti-FAK (pY397) antibodies 
were purchased from Life Technologies (Grand Island, 
NY). The anti-FAK antibody was obtained from 
Millipore (Billerica, MA). Penicillin-Streptomycin 
(pen/strep) solution was purchased from Mediatech, 
Inc. (Manassas, VA). Matrigel was obtained from 
Corning (Corning, NY) and protein assay reagent kits 
were obtained from Bio-Rad Laboratories (Hercules, 
CA). A10021B and Modified Diets were obtained from 
Central Lab. Animal, Inc. (Seoul, Korea; details in 
Supplementary Table S1).
Cell culture
The human triple-negative breast cancer cell lines 
MDA-MB-231 and Hs 578T, and mouse triple negative 
breast cancer 4T1 cells were maintained in DMEM 
containing 10% (v/v) FBS and 1% (v/v) pen/strep at 37°C 
and 5% CO2. Human breast epithelial MCF 10A cells were 
maintained in DMEM with 10% (v/v) FBS, 1% (v/v) pen/
strep, 15 mM hepes buffer, 10 μg/ml insulin and 20 ng/ml 
EGF. Each amino acid-deprived DMEM formulation was 
supplemented with 10% (v/v) dFBS and 1% (v/v) pen/
strep.
Migration assay
In order to analyze the migratory capacity of the 
TNBC cells, Essen ImageLock 96-well plates (Essen 
Instruments, Hertfordshire, UK) were coated with BD 
Matrigel (100 μg/ml culture media, BD Biosciences, 
San Jose, CA) overnight. MDA-MB-231 (4 X 10^4 
cells/well), Hs 578T (2 X 10^4 cells/well) and 4T1 
(3 X 10^4 cells/well) were then seeded on the Essen 
ImageLock plates. The cells reached confluence after 
24 hours, and mitomycin C (25 μg/ml serum free media) 
was treated 30 minutes prior to media change after 
the cells were washed with PBS. A single wound was 
made across each well automatically using a Wound 
Maker 96 Tool (Essen Instruments). The cell debris was 
washed with PBS and each amino acid-deprived media 
was applied as a treatment condition. Wound images 
were monitored with an IncuCyte Live-Cell Imaging 
System and software (Essen Instruments) and data were 
analyzed by custom algorithms in the IncuCyte software 
package.
Invasion assay
In order to determine the invasiveness of 
TNBC cells, Essen ImageLock 96-well plates (Essen 
Instruments) were coated with BD Matrigel (100 μg/
ml culture media, BD Biosciences, San Jose, CA) 
overnight. MDA-MB-231 (4 X 10^4 cells/well), Hs 
578T (2 X 10^4 cells/well) and 4T1 (3 X 10^4 cells/
well) were then seeded on the Essen ImageLock plates. 
After 24 hours, the cells reached confluence and a 
single wound was made across each well automatically 
using a Wound Maker 96 Tool (Essen Instruments). The 
cell debris was washed with PBS and each amino acid-
deprived media containing BD Matrigel (500 μg/ml) 
was applied as a treatment condition. Wound images 
were monitored with the same IncuCyte Live-Cell 
Imaging System and software (Essen Instruments) and 
data were analyzed in terms of relative wound density 
(RWD) calculated by custom algorithms in the IncuCyte 
software package.
Cell viability assay
In order to assess cell viability, MDA-MB-231 (4 X 
10^4 cells/well), Hs 578T (2 X 10^4 cells/well) and 4T1 (3 
X 10^4 cells/well) and MCF 10A (2 X 10^4 cells/well) cells 
were seeded into 96-well plates. After 24 hours, the wells were 
treated with each amino acid-deprived media formulation 
and incubated for 24 hours. MTT [3-(4,5-dimethylthiazol-
2-yl)-2.5-diphenyltetrazolium bromide] solution (final 
concentration: 0.5 mg/ml) was added to each well, and 
the cells were incubated for 1 hour. The dark formazan 
crystals that were formed by the intact cells were dissolved 
in dimethyl sulfoxide, and the absorbance at 570 nm was 
measured with a microplate reader. The results are expressed 
as percent MTT reduction relative to the absorbance of the 
control cells.
Western blot analysis
After MDA-MB-231 cells were cultured in 6-cm 
dishes for 24 hours, the cells were incubated in either 
control media or methionine-deprived media for 2, 4, 
8, or 12 hours. The cells were washed with cold PBS 
and harvested, before the protein concentration was 
measured using a protein assay reagent kit as described 
by the manufacturer. The proteins were separated 
electrophoretically using a 10% SDS-polyacrylamide gel 
and transferred onto an Immobilon P membrane (Merck 
Millipore, Billerica, MA). The membranes were blocked 
in 5% fat-free milk for 1 h, and then incubated with a 
specific primary antibody at 4°C overnight. Protein 
bands were visualized using a chemiluminescence 
detection kit (GE Healthcare, London, UK) after 
hybridization with a HRP-conjugated secondary 
antibody (Life Technologies). The bands were quantified 
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using the Image J software program ((National Institutes 
of Health, Bethesda, MD)).
Gelatin zymography
After MDA-MB-231 and Hs 578T cells were 
cultured in 6-cm dishes for 24 hours, the cells were 
incubated in either control media or methionine-deprived 
media for 24 hours. The cells were harvested on ice, 
and then centrifuged at 18,620 g for 10 min. Protein 
concentration was measured using a protein assay reagent 
kit as described by the manufacturer. The proteins were 
separated electrophoretically using a 12% polyacrylamide 
gel in the presence of gelatin (0.1% w/v) as a substrate for 
matrix metalloproteinases (MMPs). The protein samples 
were mixed with loading buffer [10% SDS, 25% glycerol, 
0.25 M Tris (pH 6.8) and 0.1% bromophenol blue], and 
then run on a 12% SDS-PAGE gel without denaturation. 
The gel was then washed with renaturating buffer (Life 
Technologies) for 1 h at room temperature and incubated 
for 24 h at 37°C in developing buffer (Life Technologies). 
After the enzyme reaction, the gel was stained with 0.5% 
Coomassie brilliant blue in 10% acetic acid. The bands 
were quantified using the Image J software program.
Real-time quantitative PCR
MDA-MB-231 cells were incubated in either 
control media or methionine-deprived media for 24 
hours and harvested using RNAiso Plus (Takara Bio Inc., 
Shiga, Japan). RNA was quantified using a NanoDrop 
ND-2000 spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA). After reverse transcription with oligo-dT 
primers using a PrimeScript™ 1st strand complementary 
DNA (cDNA) synthesis kit (Takara Bio Inc.), real-time 
quantitative RT-PCR was conducted using IQ SYBR 
(Bio-Rad Laboratories) and 2 μl of cDNA in triplicate 
with 18s rRNA as an internal control. Prior to PCR 
amplification, the primers were denatured at 95°C for 3 
min. The amplification program consisted of 44 cycles at 
95°C for 10 sec, 60°C for 30 sec, and 72°C for 30. PCR 
was performed using a CFX Connect™ Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA). 
cDNA was amplified using the following primers: MMP-
2 forward (5’-TGG CAA GTA CGG CTT CTG TC-3’); 
MMP-2 reverse (5’-TTC TTG TCG CGG TCG TAG 
TC-3’); MMP-9 forward (5’-GCA CGA CGT CTT CCA 
GTA CC-3’); MMP-9 reverse (5’-CAG GAT GTC ATA 
GGT CAC GTA GC-3’); TIMP-1 forward (5’-TGC GGA 
TAC TTC CAC AGG TC-3’); TIMP-1 reverse (5’-GCA 
TTC CTC ACA GCC AAC AG-3’); TIMP-2 forward 
(5’-AAG AGC CTG AAC CAC AGG TA-3’); TIMP-2 
reverse (5’-GAG CCG TCA CTT CTC TTG AT-3’); u-PA 
forward (5’-AGC CCT GCC CTG AAG TCG TTA-3’); 
u-PA reverse (5’-CAG GGC ATC TCC TGT GCA TG-3’); 
PAI-1 forward (5’-CTC CTG GTT CTG CCC AAG 
TT-3’); pai-1 reverse (5’-GAG AGG CTC TTG GTC 
TGA AAG-3’) ; 18s rRNA forward (5’-GTA ACC CGT 
TGA ACC CCA TT-3’); 18s rRNA reverse (5’-CCA TCC 
AAT CGG TAG TAG CG-3’). Relative quantitation was 
performed using the comparative ΔΔCt method following 
the manufacturer’s instructions.
Animals
Eight-week-old female BALB/c mice were 
purchased from Orient Bio Inc. (Seongnam, Korea). 
Animals were acclimated for 5 days prior to the study 
and had free access to food and water. All experimental 
protocols were approved by the Institutional Animal Care 
and Use Committee (Case Number: SNU-141006-4) of 
Seoul National University, Seoul, Korea. The animals 
were housed in climate-controlled quarters (24°C at 50% 
humidity) with a 12 h light/12 h dark cycle.
In vivo lung metastasis experiments
4T1 cells were harvested and diluted in sterile PBS. 
The cells (2 x 10^5 cells/mouse) were injected into the 
tail veins of nine-week-old female BALB/c mice. On the 
day of the injection, the mice were divided randomly into 
3 treatment groups and diets were modified accordingly 
with the following: 1) control diet, 2) 0.1% methionine 
containing diet, 3) methionine-deprived diet. The food 
and water were supplied ad libitum. Ten days after the 
injection, all mice were sacrificed and the lungs and 
livers were isolated and weighed. The lungs were fixed 
in Bouin’s solution (Sigma-Aldrich, St.Louis, MO) to 
quantify tumor nodules.
Statistical analysis
Statistical analysis was performed using one-way 
ANOVA followed by Duncan’s Multiple Range Test, and 
p values of less than 0.05 were considered statistically 
significant.
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